Liquid Biopsy is a conventional method used to diagnose
onset of cancer. The alternative names for liquid biopsy are fluid biopsy or
fluid phase biopsy. This is largely a non-invasive method used to track tumors
and mutations over a period of time. Doctors are informed about the disease
with the help of these observations of the tumor’s future. Though being simple
and instrumental in early stage detection of cancer, it voices concerns over
its adoption. Liquid Biopsy products
market has a shortcoming which is it is largely overshadowed by tissue biopsy
with the latter being adopted exceptionally.
The global liquid biopsy market size is slated to reach USD
3,362.6 million by 2026 at a CAGR of 21.9% according to a news report published
by Polaris Market Research.
Get sample Copy @ https://www.polarismarketresearch.com/industry-analysis/liquid-biopsy-market/request-for-sample
A significant driver to growth of liquid biopsy is the
reduced number of surgical invasions. This encouraging sign makes it one of the
most adopted substitutes for tissue biopsy. An increasing trend followed by key
players to shift focus onto research and development activities aiding
strategic M&A improves market strength dramatically. Considering the basis
of technology, single gene analysis and multi-gene-parallel analysis (NGS)
dominate the liquid biopsy cancer market size. NGS denotes diagnosis of
multiple diseases at one instance. PCR is an approach to analyzing mutation
among genes.
Yet another class of distinction in liquid biopsy market
2018 is based on sample type. The sample is segmented on basis of blood,
saliva, urine and other body fluid. Blood sample is the best sample type for
customary analyses as blood contains cell free DNA, circulating cell and
exosomes that offer them for easy detection leading to detection of cancerous
cells in human body.
Based on biomarker type, the global market outlook to 2026
is segmented into exosomes, circulating tumor cells (CTC) and circulating tumor
DNA (ctDNA). CTC biomarkers govern largest market share owing to high awareness
levels and accurate tracking results of cancerous cells in the body. CTC marker
makes early forays in the initial stages of detection of cancer itself.
North America is
holding coveted position as per geography in market cap during forecast period.
Increased facilitators for diagnosis of cancer and rising number of patients
suffering from cancer are factors promoting growth of market. Asia Pacific is
exhibited to grow at a faster rate during forecast period.
Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/liquid-biopsy-market/request-for-discount-pricing
The major players operating in market include Roche
Diagnostics, Illumina Inc., Myriad Genetics, Inc., RainDance Technologies, Inc.
among others.
About Polaris Market Research
Polaris Market Research is a
global market research and consulting company. The company specializes in
providing exceptional market intelligence and in-depth business research
services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
No comments:
Post a Comment
Please do not enter any spam link in the comment box...